Gsa Capital Partners LLP Tricida, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$7.31 - $11.85 $168,005 - $272,348	-22,983 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$7.35 - $10.63 $1.64 Million - $2.37 Million	-222,516 Reduced 90.64%	22,983 $189,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $1.53 Million - $3.49 Million	-365,549 Reduced 59.82%	245,499 $2.35 Million
Q3 2021 Nov 12, 2021	BUY	$3.56 - $4.64 $1.13 Million - $1.47 Million	317,087 Added 107.87%	611,048 $2.84 Million
Q2 2021 Aug 05, 2021	BUY	$3.95 - $5.41 $1.16 Million - $1.59 Million	293,961 New	293,961 $1.27 Million
Q4 2020 Feb 03, 2021	SELL	$4.37 - $9.46 $58,776 - $127,237	-13,450 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$8.56 - $26.93 $115,132 - $362,208	13,450 New	13,450 $122,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.